Protocol CA057-1040 is an open-label, multicenter, Phase 1b/2a study evaluating mezigdomide in combination with elranatamab in participants with relapsed and/or refractory multiple myeloma (RRMM). The primary objectives are to determine the recommended dose and schedule (RP2D) and to evaluate safety and preliminary clinical efficacy. Eligible participants are adults who have received at least three prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody. Participants must show documented disease progression on or after their most recent therapy. The study design consists of a dose-escalation phase followed by a dose-expansion phase. Key secondary endpoints include overall response rate (ORR), duration of response (DOR), and progression-free survival (PFS).
BMS CA057-1040 - This clinical study evaluates a new combination treatment for patients with multiple myeloma whose disease has returned or stopped responding to previous therapies. The study combines two drugs, mezigdomide and elranatamab, to test their safety and how well they work together. One primary goal is to determine the most effective and safe dose for participants. Adults whose cancer has progressed after at least three prior types of treatment may be eligible to join. Participants receive the medication while doctors closely monitor their health and the treatment’s effect on the cancer.
